Get the Stockscreener App
6.33
3.09%
0.19
After Hours:
6.20
-0.13
-2.05%
Verastem Inc stock is traded at $6.33, with a volume of 2.02M.
It is up +3.09% in the last 24 hours and up +13.04% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.14
Open:
$6.3
24h Volume:
2.02M
Relative Volume:
1.08
Market Cap:
$556.05M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-1.9021
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+16.15%
1M Performance:
+13.04%
6M Performance:
-32.66%
1Y Performance:
+31.60%
1-Day Range:
$6.215
$6.5789
1-Week Range:
$5.23
$6.5789
52-Week Range:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.33 | 539.36M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
PI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, - openPR.com
Chipmakers Recap: How is Verastem Inc managing supply chain issues2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Aug Wrap: What analysts say about Verastem Inc stock2026 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com - Investing.com Canada
Sentiment Recap: What analysts say about Verastem Inc stockTrade Entry Report & AI Optimized Trade Strategies - baoquankhu1.vn
Verastem Oncology’s combo shows two-year durability in ovarian cancer - MSN
Fed Meeting: What is the Moat Score of Verastem IncQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Today's Analyst Rating Data for VSTM: Maintained Buy Rating | VS - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 | VSTM Stock News - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 - GuruFocus
Verastem stock maintains Buy rating at BTIG on durable trial data - Investing.com Canada
Verastem (VSTM) Presents Positive Two-Year Data for Ovarian Canc - GuruFocus
Verastem’s cancer drug combo shows durability in 2-year data By Investing.com - Investing.com India
Verastem’s cancer drug combo shows durability in 2-year data - Investing.com
Verastem Oncology announces two-year median follow-up data on Avmapki® Fakzynja® combination therapy - marketscreener.com
Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy - TradingView — Track All Markets
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s C - Business Wire
Weekly Trades: What analysts say about Verastem Inc stockCEO Change & Weekly High Potential Alerts - baoquankhu1.vn
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem (Nasdaq: VSTM) boosts equity and ESPP share pools for employees - Stock Titan
Understanding Momentum Shifts in (VSTM) - Stock Traders Daily
Working capital per share of Verastem, Inc. – MUN:2VSA - TradingView — Track All Markets
VSTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance UK
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com
Alison Lawton and Michael Kauffman Join Verastem Board of Directors - Yahoo
Verastem, Inc. (2VSA.F) stock price, news, quote and history - Yahoo Finance Singapore
Verastem Oncology announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Stephen Sherwin, M.D., Joins Verastem Board of Directors - yahoo.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com
Verastem (VSTM): Jefferies Lowers Price Target but Retains 'Buy' Rating | VSTM Stock News - GuruFocus
Verastem's (VSTM) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15 - Moomoo
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Jefferies lowers Verastem stock price target on valuation refresh - Investing.com UK
Jefferies lowers Verastem stock price target on valuation refresh By Investing.com - Investing.com India
Vanguard disaggregates holdings; reports 0 shares of Verastem (NASDAQ: VSTM) - Stock Titan
Cancer Stocks Worth Considering as Breakthroughs Transform the Worldwide Oncology Industry - Bitget
Verastem (VSTM) CFO receives 57-share stock award in Form 4 - stocktitan.net
Market Moves: What analysts say about Verastem Inc stock2026 Earnings Surprises & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha
Verastem Oncology drops despite Q3 double beat - MSN
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union
FinancialContentVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - FinancialContent
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):